Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer

Summary

This phase II trial evaluated the impact of Oxaliplatin and Gemcitabine in patients with recurrent or advanced transitional cell carcinoma of the bladder. The combination of Oxaliplatin and Gemcitabine is considered investigational and this study will help in determining if their activity and toxicity profiles are comparable or better than the standard regimens.

Timeline

Start

2005-01-20

Primary completion

2011-10-06

Completion

2011-10-06

Outcome

Outcome not reported

Stopped (Business): “Trial was terminated due to halt in funding.”

Drugs

Indications